How an industry actually grows: pharma in a small economy
Pharma looks like a science story. It's mostly a manufacturing, regulation and pricing story. A worked example of why sectors grow.
The question
"Country X's pharma industry is growing" is a headline, not an explanation. Why do some pharmaceutical sectors scale and others stall? Strip the headline and what actually drives the growth?
What's happening
Pharma is treated as a high-tech story — labs and discovery. In practice, in most emerging economies the growth that shows up in the numbers is lower down the chain: generic manufacturing and active pharmaceutical ingredients (APIs), not novel drug discovery.
How it actually works
An industry scales when four gears turn together. Miss one and growth stalls:
| Gear | What it is | What blocks it |
|---|---|---|
| Manufacturing capability | producing at scale, to spec, reliably | capital, quality systems |
| Regulation | approvals that unlock export markets | audits, standards, certification |
| Cost base | why production lands here | labour, energy, logistics |
| Pricing access | who buys it, and on what terms | tenders, patents, trade rules |
The mechanism is sequential:
- A country usually starts by making generics for its own market — the easiest rung, because the regulator is close and the buyer is domestic.
- Growth comes when regulatory approval abroad lets it export. Approval is the hinge: without a recognized certification, the manufacturing capacity has nowhere to sell.
- Real scale arrives when cost advantages (skilled labour, lower energy) let the country win contracts in other markets — this is where API production clusters form.
- The ceiling is set by pricing and patents. Off-patent molecules are a commodity race to the bottom; novel molecules are locked behind patent walls and huge R&D budgets.
That is why "pharma growth" is rarely about a discovery. It is a story about certification, cost curves and who gets to sell to whom.
The science is necessary. The growth is decided by manufacturing, regulation and price.
What's unknown
- How much of the growth is durable versus a function of a single export market's demand.
- Whether the sector can move up the chain from generic manufacturing to research, or whether that step requires a scale of capital small economies cannot raise.
- Open: the certification bottleneck is the fascinating part and the one I understand least — how a local manufacturer actually earns the approval to export.
Reading
- Pharmaceutical supply-chain and API-manufacturing analyses.
- Trade/regulatory material on drug certification and export approval.